Skip to search formSkip to main contentSkip to account menu

alicaforsen

National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antisense OligonucleotidesGastrointestinal AgentsImmunosuppressive AgentsPhosphorothioate Oligonucleotides

Narrower (1)

ISIS 2302

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Second-Generation Compounds Advance : Phase 2 a Biomarker Trial of ISIS 104838 in Patients with Rheumatoid Arthritis
  • 2018
  • Corpus ID: 53576237
CARLSBAD, Calif., Oct. 27 /PRNewswire-FirstCall/ -Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced positive data from… 
Review
2015
Review
2015
Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges
Despite the great success of anti-tumour necrosis factor-based therapies, the treatment of Crohn’s disease (CD) and ulcerative… 
Review
2014
Review
2014
Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis
Pouchitis is a relatively common complication that develops following ileal pouch-anal anastomosis in patients with complicated… 
2013
2013
Meta‐analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis
The antisense ICAM‐1 inhibitor alicaforsen has been studied in four phase 2 studies in ulcerative colitis (UC). Recruited… 
2005
2005
Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM‐1 *
Serological profiles for anti‐Saccharomyces cerevisiae antibodies (ASCA)/ perinuclear antineutrophil cytoplasmic antibodies… 
2004
2004
escalating dose study of alicaforsen enema in active ulcerative colitis
Objective: To evaluate the safety and efficacy of an enema formulation of alicaforsen, an antisense inhibitor of intercellular… 
2004
2004
Making sense of antisense: ISIS 2302 (alicaforsen) in the treatment of pouchitis. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of…
2004
2004
RESPONSE OF THE GASTROINTESTINAL & PULMONARY SYMPTOMS OF CHURG-STRAUSS SYNDROME (CSS) TO TREATMENT WITH AN ANTISENSE INHIBITOR TO ICAM-1 (ALICAFORSEN): 527
Highly Cited
2002
Highly Cited
2002
Dose ranging pharmacokinetic trial of high‐dose alicaforsen (intercellular adhesion molecule‐1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease
Background and aims : To evaluate the safety, pharmacokinetics and clinical efficacy of the intercellular adhesion molecule‐1… 
2002
2002
INFLAMMATORY BOWEL DISEASE Double blind , placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide , alicaforsen ( ISIS 2302…
Background and aims: To evaluate the safety and efficacy of the intercellular adhesion molecule 1 (ICAM-1) antisense… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)